key: cord-0703775-t5gc17rs
authors: San-Juan, Rafael; Fernández-Ruiz, Mario; López-Medrano, Francisco; Carretero, Octavio; Lalueza, Antonio; de la Calle, Guillermo Maestro; Asín, María Asunción Pérez-Jacoiste; Bueno, Héctor; Caro-Teller, José Manuel; Catalán, Mercedes; de la Calle, Cristina; García-García, Rocío; Gómez, Carlos; Laguna-Goya, Rocío; Lizasoáin, Manuel; Martínez-López, Joaquín; Origüen, Julia; Sevillano, Ángel; Gutiérrez, Eduardo; de Miguel, Borja; Aguilar, Fernando; Parra, Patricia; Ripoll, Mar; Ruiz-Merlo, Tamara; Trujillo, Hernando; Pablos, José Luis; Paz-Artal, Estela; Lumbreras, Carlos; Aguado, José María
title: Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
date: 2022-01-23
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.01.040
sha: 3e135438c2180c37588bbc7ac75209644aa5ead4
doc_id: 703775
cord_uid: t5gc17rs

Background : Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods : We retrospectively analyzed a cohort of patients with severe COVID-19 admitted to the University Hospital “12 de Octubre” until May, 2020 that received off-label TCZ after indication of a local Committee. The primary end point was significant clinical improvement at day 14 after TCZ (SCI). Factors independently related with SCI were analyzed by multivariate logistic regression models. Results : Out of 428 patients treated with TCZ, 271(63.3%) experienced SCI. After adjustment by factors related with unfavorable outcome, TCZ administration within the first 48 hours from admission (odds ratio [OR]: 1.98, 95% confidence Interval [95% CI]: 1.1 – 3.55; P-value = 0.02) and ALT levels >100 UI/L at day 0 (OR: 3.28; 95% CI:1.3 –8.1; P-value = 0.01) were independently related with SCI. The rate of SCI significantly decreased according timing of TCZ: 70.2% first 48 hours from admission, 58.5% day 3 to 7 and 45.1% beyond day 7 (P-values = 0.03 and 0.001 respectively). Conclusion : TCZ improves the prognosis of patients with COVID-19 mostly if treatment is started within the first 48 hours of admission.

 Improvement at 14 days occurs in 63.3% of severe COVID-19 treated with tocilizumab.

 Early administration of tocilizumab is associated with better clinical response.

 A recruitment window of 48 hours from admission in tocilizumab RCTs is advisable.

13. Department of Nephrology, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain. † Other members are listed in the Appendix. 

Since the early beginning of the pandemics, the deleterious impact of the hyperactive immune response triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported (Giamarellos-Bourboulis et al., 2020 , Vabret et al., 2020 and therapeutic immunomodulation emerged as a potentially life-saving option for patients with severe coronavirus disease 2019 (COVID-19) (Luis et al., 2021) . Available drugs inhibiting the pleiotropic proinflammatory cytokine IL-6 rapidly turned of particular interest, since elevated IL-6 levels seemed to mediate systemic inflammatory responses associated to SARS-CoV-2 infection and the development of acute respiratory distress syndrome (ARDS) and multiorgan failure (McGonagle et al., 2020) . Preliminary case series and cohort studies reported outcomes in patients with severe COVID-19 pneumonia treated off-label with intravenous (IV) or subcutaneous (SC) tocilizumab (TCZ), the humanized monoclonal antibody targeting the IL-6 receptor (IL-6R) most available at that time (Antwi-Amoabeng et al., 2020 , Fernandez-Ruiz et al., 2021b , Jordan et al., 2020 , Knorr et al., 2020 , Toniati et al., 2020 , with preliminary data suggesting the safety and potential efficacy of this approach. These early results rapidly prompted the incorporation of this agent in most COVID-19 management protocols pending the results of observational studies and randomized clinical trials (RCTs) investigating the real role of TCZ for this indication.

Contradictory results were firstly obtained from observational studies. Although most of these studies found benefits in form of decreased mortality or invasive mechanical ventilation (IMV) requirements among TCZ-treated patients (Deftereos et al., 2020 , Mikulska et al., 2020 , Rojas-Marte et al., 2020 , Rossotti et al., 2020 , Roumier et al., 2021 , Somers et al., 2020 , some others failed to demonstrate significant outcome differences compared to the standard of care (Campochiaro et al., 2020 , Della-Torre et al., 2020 . Surprisingly, similar variable results are currently being reported from RCTs. Although recent metaanalyses including all the 10 RCTs with available results up to May 2021 (Snow et al., 2021 , Tleyjeh et al., 2021 found an overall statistically significant but modest benefit in terms of mortality in the most severe patients and a trend for lower risk of progression to IMV, the specific results from placebo-controlled RCTs failed to demonstrate a significant prognostic effect (Rosas et al., 2021 , Stone et al., 2020 . In these regard, there is a need to identify specific factors that would prompt tocilizumab use and some experts are currently claiming for the identification of the clinical profile of the patients most likely to be respondents to TCZ therapy in order to optimize the results of this potentially effective treatment for severe COVID-19 (Fernandez-Ruiz et al., 2021a , Klopfenstein et al., 2021 .

The aim of the present study was to analyze the baseline clinical factors related with clinical response in a broad homogeneous cohort of patients that received off-label treatment with TCZ under an institutional protocol throughout the first COVID-19 pandemic wave.

This retrospective study was conducted at the University Hospital "12 de

Octubre" (Spain 

Quantitative data were shown as the mean and standard deviation (SD) or the median with interquartile range (IQR), whereas qualitative variables were expressed as absolute and relative frequencies. Results are given as odds ratios (ORs) with 95% confidence intervals (CIs).

All the significance tests were two-tailed. The threshold for significance was set at a P-value <0.05. Statistical analysis was performed with SPSS version 20.0 (IBM Corp., Armonk, NY) and graphs were generated with Prism version 6.0 (GraphPad Software Inc., La Jolla, CA).

After excluding 7 patients with insufficient follow-up data due to transfer to another institution, a total of 428 patients were included in the analysis. As shown in Table 1 and Table 2 , most patients were male, of Caucasian ethnicity, with a mean age of 55 years, more than half with some underlying disease and presented to the Emergency Department with cough, dyspnea and diffuse infiltrates on the initial chest X-ray after a median interval of 7 days since symptom onset. Most patients were treated with HCQ, half of them received corticosteroid therapy, and about one third received LPV/r prior to or simultaneously with the first dose of TCZ. Empiric antibiotic therapy including second-or third-generation cephalosporins or amoxicillin/clavulanic acid was also common.

Clinical and analytical data of patients at the time of TCZ administration are depicted in Table 3 . According to the clinical criteria for being considered as candidates for TCZ by the Multidisciplinary Committee, one single criteria was fulfilled in 13 (3.0%) of them, two criteria in 80 (18.7%), three in 207 (48.4%), four in 116 (27.1%) and five in 12 (2.8%). TCZ was administered mainly at single dose schedule at a median of two days from hospital admission. 

The preliminary comparative analysis between patients presenting or not SCI by day +14 is shown in Hepatitis expressed by serum ALT levels >100 IU/L also defined a group of patients with a three-fold increased odds of having a favorable response to TCZ therapy (OR: 3.28; 95% CI: 1.3 -8.1; P-value = 0.01).

Although the groups of patients stratified by the timing of TCZ administration (within the first 48 hours of admission or beyond) were not entirely comparable (Table S1) , different comorbidity and disease severity variables were also included in the final multivariate model. Early (first 48 hours) initiation of TCZ therapy still retained the statistical significance after such adjustment.

A specific analysis of this large series of patients treated with IV TCZ has allowed us to elucidate the factors that may predict a significant clinical response to this immunomodulatory agent in patients with COVID-19. An advantage of this series was the homogeneity in the indications for treatment with TCZ since all patients were selected by a specific committee which applied pre-stablished criteria. All the patients presented bilateral infiltrates on chest Xray or CT scan, elevated serum CRP levels and respiratory deterioration, pneumonia has been generally advised and specifically recommended in most compassionate off-label protocols from the beginning of the pandemics (Mikulska et al., 2020 , Moreno Diaz et al., 2021 . Although a maximum interval of 48 hours from admission was considered as inclusion criteria in one particular RCT (Salama et al., 2021) , no details on the recruitment windows were reported in the majority of published trials (Snow et al., 2021) . The impact of the timing of TCZ administration in the clinical response rates had not been accurately analyzed to date. In two previous reports, the potential prognostic benefit of early treatment with TCZ was suggested, although the limited sample included in these studies precluded from performing multivariate analyses to adequately confirm this finding (Martinez-Urbistondo et al., 2021 , Moreno Diaz et al., 2021 .According to the findings of the present study, a rational conclusion is that patients who reached criteria soon after hospital admission and were in inflammatory phase may benefit more from TCZ administration and we therefore recommend a practical approach work-up including the early detection of patients with COVID-19 bilateral pneumonia fulfilling criteria of hyper inflammatory stage of the disease at the emergency room with daily reevaluation so as to begin TCZ treatment before development of severe ARDS.

Unexpectedly, the finding of hypertransaminasemia (serum ALT levels >100 IU/L) at the time of treatment initiation was also found to act as an independent marker of subsequent response to TCZ. The explanation of this finding is not clear. Efficacy of TCZ is assumed to be more probable when administered in the hyperinflammatory state of COVID-19 (Rodriguez-Bano et al., 2021) , and liver inflammation is considered by some experts as a complication due to immune damage rather than direct viral cytopathic effect (Wu et al., 2021) . We postulate that high ALT levels could potentially identify patients at the hyperinflammatory state of the disease. Previous use of statins was related with near a three-fold risk of TCZ failure, which could be explained -in line to what has been shown in a particular study (Mitacchione et al., 2021 )-by the potential role of this variable as a subrogate marker of underlying cardiovascular disease, conferring a higher risk of more severe COVID-19 disease.

The profile of patients with favorable response to TCZ therapy in our study was also defined by the absence of major underlying diseases potentially related with a worse outcome, such as active malignancy or the presence of advanced disease with severe respiratory deterioration (as indicated by higher values of CRP or LDH and lower SpO2/FiO2 ratios) ( Table 6 ). Such factors have been previously related with poor outcome (Richardson et al., 2020 , Wu et al., 2020 , Zhou et al., 2020 and efficacy of TCZ has been shown to be lower in advanced stages of SARS-CoV-2-related ARDS (Moiseev et al., 2020) . Age was not an independent risk factor for clinical failure in our cohort probably due to the relatively young population included (only one third over 60 years old).

Some limitations of the present research deserve specific consideration. This is a single-center study including patients over the first pandemic wave in Madrid, which entailed overwhelming of health resources and limited access of potentially effective therapeutic alternatives as remdesivir that could have influenced in the late access to hospital care. Therefore, extrapolation to other centers in different stages of the pandemic should be done with caution. In contrast to the timing from admission, the time interval between symptom onset and TZC administration was not found to have significant influence in clinical response. A possible explanation of this apparent discrepancy could reside on the lower accuracy of the precise calendar date for the initiation of symptoms self-reported by the patient in comparison with the more objective time point expressed by the date of admission. On the other hand, we belief that the beginning of the inflammatory phase of infection is more closely related with the time of symptoms worsening represented by the date of hospital admission.

Since stringent criteria were applied to select candidates to TCZ therapy, the present cohort may not be representative of the entire COVID-19 population, particularly elderly patients that were underrepresented in the present cohort.

Finally, although the large sample allowed us to perform a robust multivariate model to adequately adjust the main prognostic factors, we cannot rule out the impact of unmeasured confounding factors due to the retrospective nature of the study and the absence of a control group precludes from addressing the potential effect of other administered treatments. In these regard, the heterogeneity in the doses and duration of corticosteroids patients receiving coadministration of corticosteroids that could influence therapeutic outcomes (Khiali and Entezari-Maleki, 2021) , the changes of the treatment guidelines during the study period and the effects of other therapies alongside corticosteroids in each group are other limitations of the study.

In conclusion, the results of the present study support the early initiation of TCZ therapy in patients with severe COVID-19 and prompt the incorporation of a recruitment window of 48 hours from admission in future RCTs in order to eventually optimize the efficacy of this treatment.

García-Ruiz de Morales and Dr. Guillermo Chiara-Graciani for their assistance throughout the study.

The authors would like to acknowledge all the health-care workers involved in the response to the current pandemic in our hospital and, singularly, those who suffered COVID-19.

This research was supported by "Plan Nacional de I+D+I" and Instituto de Salud Innovation.

The Clinical Research Ethics Committee approved the study protocol (CEIm no. 20/117) and granted a waiver of informed consent in view of the observational design.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Tocilizumab for the treatment of COVID-19

Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy

It is time to determine Tocilizumab place in COVID-19

Tocilizumab in patients with severe COVID-19: A single-center observational analysis

Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Antiinflammatory Therapy for Severe Coronavirus Disease (COVID)

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

Documento técnico de manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19) (versión 3 de Marzo de 2020)

China/documentos/Protocolo_manejo_clinico_COVID-19.pdf

Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy

Neither earlier nor late

Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis-first update

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in

Immunology of COVID-19: Current State of the Science

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

CRP: C-reactive protein; ECMO: extracorporeal membrane oxygenation; IQR: interquartile range; IMV: invasive mechanical ventilation; LDH: lactate dehydrogenase; NIMV: non-invasive mechanical ventilation

SpO2/FiO2

Ferritin at day 0, ng/mL

ALT: alanine transaminase; AST: aspartate transaminase; bpm: beats per minute; CI: confidence interval; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; HCQ: hydroxychloroquine; IFN-β: interferon-β

LDH: lactate dehydrogenase

LPV/r: lopinavir/ritonavir; NEWS: National Early Warning Score; rpm: respirations per minute; OR: odds ratio; SAHS: sleep apnea-hypopnea syndrome

SpO2/FiO2: SpO2/FiO2: pulse oximetry oxygen saturation/fraction of inspired oxygen

We thank Dr. Miguel Saro-Buendía, Dr. Ángel Marrero-Sánchez, Dr. DanielThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: